会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
    • 可用于治疗认知障碍的α-氨基酰胺衍生物
    • US08741957B2
    • 2014-06-03
    • US12304455
    • 2007-06-13
    • Patricia SalvatiStefano RossettiLuca Benatti
    • Patricia SalvatiStefano RossettiLuca Benatti
    • A61K31/165A61K31/404A61K31/085A61K31/135A61K31/341A61K31/402
    • A61K31/404A61K31/085A61K31/135A61K31/165A61K31/341A61K31/402
    • The present invention is in the field of pharmacotherapy of cognitive deficits in learning and memory by administering an α-aminoamide, particularly safinamide. Examples of disturbances in cognition that can be treated with compounds of the invention are the ones associated with disorders such as autism, dyslexia, attention deficit hyperactivity disorder, schizophrenia, obsessive compulsive disorders, psychosis, bipolar disorders, depression, Tourette's syndrome, Mild Cognitive Impairment (MCI) and disorders of learning in children, adolescents and adults, Age Associated Memory Impairment, Age Associated Cognitive Decline, Alzheimer's Disease, Parkinson's Disease, Down's Syndrome, traumatic brain injury Huntington's Disease, Progressive Supranuclear Palsy (PSP), HIV, stroke, vascular diseases, Pick's or Creutzfeldt-Jacob diseases, multiple sclerosis (MS), other white matter disorders and drug-induced cognitive worsening.
    • 本发明通过给予α-氨基酰胺,特别是safinamide,在学习和记忆中的认知缺陷的药物治疗领域。 可以用本发明化合物治疗的认知障碍的例子是与自闭症,阅读困难,注意缺陷多动障碍,精神分裂症,强迫症,精神病,双相情感障碍,抑郁症,Tourette综合征,轻度认知障碍 (MCI)和儿童,青少年和成年人学习障碍,年龄相关记忆障碍,年龄相关认知衰退,阿尔茨海默病,帕金森病,唐氏综合征,创伤性脑损伤亨廷顿病,进行性核核麻痹(PSP),艾滋病毒,中风, 血管疾病,Pick's或Creutzfeldt-Jacob疾病,多发性硬化症(MS),其他白质病症和药物诱导的认知恶化。
    • 2. 发明申请
    • ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS
    • 用于治疗认知障碍的ALPHA-氨基酰胺衍生物
    • US20100016437A1
    • 2010-01-21
    • US12304455
    • 2007-06-13
    • Patricia SalvatiStefano RossettiLuca Benatti
    • Patricia SalvatiStefano RossettiLuca Benatti
    • A61K31/195A61K31/165A61P25/00
    • A61K31/404A61K31/085A61K31/135A61K31/165A61K31/341A61K31/402
    • The present invention is in the field of pharmacotherapy of cognitive deficits in learning and memory by administering an α-aminoamide, particularly safinamide. Examples of disturbances in cognition that can be treated with compounds of the invention are the ones associated with disorders such as autism, dyslexia, attention deficit hyperactivity disorder, schizophrenia, obsessive compulsive disorders, psychosis, bipolar disorders, depression, Tourette's syndrome, Mild Cognitive Impairment (MCI) and disorders of learning in children, adolescents and adults, Age Associated Memory Impairment, Age Associated Cognitive Decline, Alzheimer's Disease, Parkinson's Disease, Down's Syndrome, traumatic brain injury Huntington's Disease, Progressive Supranuclear Palsy (PSP), HIV, stroke, vascular diseases, Pick's or Creutzfeldt-Jacob diseases, multiple sclerosis (MS), other white matter disorders and drug-induced cognitive worsening.
    • 本发明通过施用α-氨基酰胺,特别是safinamide,在学习和记忆中的认知缺陷的药物治疗领域。 可以用本发明化合物治疗的认知障碍的例子是与自闭症,阅读困难,注意缺陷多动障碍,精神分裂症,强迫症,精神病,双相情感障碍,抑郁症,Tourette综合征,轻度认知障碍 (MCI)和儿童,青少年和成年人学习障碍,年龄相关记忆障碍,年龄相关认知衰退,阿尔茨海默病,帕金森病,唐氏综合征,创伤性脑损伤亨廷顿病,进行性核核麻痹(PSP),艾滋病毒,中风, 血管疾病,Pick's或Creutzfeldt-Jacob疾病,多发性硬化症(MS),其他白质病症和药物诱导的认知恶化。